Compare UAC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UAC | EQ |
|---|---|---|
| Founded | 2025 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 129.0M |
| IPO Year | 2026 | 2018 |
| Metric | UAC | EQ |
|---|---|---|
| Price | $9.93 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 4.0K | ★ 922.5K |
| Earning Date | N/A | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.51 | $0.29 |
| 52 Week High | $9.97 | $3.45 |
| Indicator | UAC | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 61.60 |
| Support Level | $9.51 | $1.54 |
| Resistance Level | $9.96 | $3.45 |
| Average True Range (ATR) | 0.01 | 0.35 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 52.94 | 65.57 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.